|
Name |
8-Acetylneosolaniol
|
Molecular Formula | C21H28O9 | |
IUPAC Name* |
[(1S,2R,4S,7R,9R,10R,11S,12S)-4,11-diacetyloxy-10-hydroxy-1,5-dimethylspiro[8-oxatricyclo[7.2.1.02,7]dodec-5-ene-12,2'-oxirane]-2-yl]methyl acetate
|
|
SMILES |
CC1=C[C@@H]2[C@](C[C@@H]1OC(=O)C)([C@]3([C@@H]([C@H]([C@H]([C@@]34CO4)O2)O)OC(=O)C)C)COC(=O)C
|
|
InChI |
InChI=1S/C21H28O9/c1-10-6-15-20(8-26-11(2)22,7-14(10)28-12(3)23)19(5)17(29-13(4)24)16(25)18(30-15)21(19)9-27-21/h6,14-18,25H,7-9H2,1-5H3/t14-,15+,16+,17+,18+,19+,20+,21-/m0/s1
|
|
InChIKey |
BIQPSTSCCIEMEI-HXZSLLSJSA-N
|
|
Synonyms |
8-Acetylneosolaniol; 65041-92-1; [(1S,2R,4S,7R,9R,10R,11S,12S)-4,11-diacetyloxy-10-hydroxy-1,5-dimethylspiro[8-oxatricyclo[7.2.1.02,7]dodec-5-ene-12,2'-oxirane]-2-yl]methyl acetate; Neosolaniol monoacetate; Neosoloaniol monoacetate; 2X9JH5APS4; Trichothec-9-ene-3,4,8,15-tetrol, 12,13-epoxy-, 4,8,15-triacetate, (3alpha,4beta,8alpha)-; UNII-2X9JH5APS4; CHEMBL152165; 3-Hydroxy-4beta,8-alpha,15-triacetoxy-12,13-epoxytrichothec-9-ene; 4-beta,8-alpha,15-Triacetoxy-3-alpha-hydroxy-12,13-epoxytrichothec-9-ene; Trichothec-9-ene, 12,13-epoxy-4-beta,8-alpha,15-triacetoxy-3-alpha-hydroxy-; Trichothec-9-ene-3-alpha,4-beta,8-alpha,15-tetrol, 12,13-epoxy-, 4,8,15-triacetate
|
|
CAS | 65041-92-1 | |
PubChem CID | 13879996 | |
ChEMBL ID | CHEMBL152165 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 424.4 | ALogp: | -0.3 |
HBD: | 1 | HBA: | 9 |
Rotatable Bonds: | 7 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 121.0 | Aromatic Rings: | 4 |
Heavy Atoms: | 30 | QED Weighted: | 0.306 |
Caco-2 Permeability: | -5.401 | MDCK Permeability: | 0.00007010 |
Pgp-inhibitor: | 0.255 | Pgp-substrate: | 0.997 |
Human Intestinal Absorption (HIA): | 0.298 | 20% Bioavailability (F20%): | 0.734 |
30% Bioavailability (F30%): | 0.976 |
Blood-Brain-Barrier Penetration (BBB): | 0.503 | Plasma Protein Binding (PPB): | 27.14% |
Volume Distribution (VD): | 1.153 | Fu: | 49.84% |
CYP1A2-inhibitor: | 0.023 | CYP1A2-substrate: | 0.103 |
CYP2C19-inhibitor: | 0.024 | CYP2C19-substrate: | 0.405 |
CYP2C9-inhibitor: | 0.009 | CYP2C9-substrate: | 0.021 |
CYP2D6-inhibitor: | 0.059 | CYP2D6-substrate: | 0.093 |
CYP3A4-inhibitor: | 0.463 | CYP3A4-substrate: | 0.378 |
Clearance (CL): | 2.39 | Half-life (T1/2): | 0.68 |
hERG Blockers: | 0.042 | Human Hepatotoxicity (H-HT): | 0.67 |
Drug-inuced Liver Injury (DILI): | 0.9 | AMES Toxicity: | 0.952 |
Rat Oral Acute Toxicity: | 0.34 | Maximum Recommended Daily Dose: | 0.107 |
Skin Sensitization: | 0.461 | Carcinogencity: | 0.091 |
Eye Corrosion: | 0.006 | Eye Irritation: | 0.042 |
Respiratory Toxicity: | 0.34 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003278 | 0.874 | D0OL7F | 0.316 | ||||
ENC003104 | 0.854 | D09SIK | 0.316 | ||||
ENC001179 | 0.826 | D0L2UN | 0.296 | ||||
ENC003580 | 0.817 | D0G7KJ | 0.291 | ||||
ENC003086 | 0.767 | D08BDT | 0.272 | ||||
ENC005517 | 0.734 | D09WYX | 0.263 | ||||
ENC005516 | 0.711 | D03ZZK | 0.261 | ||||
ENC005586 | 0.585 | D0X7XG | 0.261 | ||||
ENC005587 | 0.412 | D0H2MO | 0.259 | ||||
ENC002198 | 0.336 | D0Q6DX | 0.253 |